
    5 patients on tivicay had virological failure
  
['hiv']
['dolutegravir 50mg +abacavir 600mg +lamivudine 300mg', 'dolutegravir']

        Inclusion Criteria:

          -  HIV-1-infected patients with no previous AIDS event (excluding a healed tuberculosis);

          -  Current antiretroviral treatment associating dolutegravir + abacavir + lamivudine for
             at least 1 month;

          -  Nadir CD4 ≥ 100/mm3;

          -  Plasma RNA viral load < 50 copies/ml for at least 12 months;

          -  Plasma RNA viral load <20 or 40 copies/ml (according to the threshold of the method
             used by local laboratory) at the screening visit;

          -  No documented virologic failure or known resistance to any integrase inhibitor,

          -  Patient having provided a written consent;

          -  Patients follow-up possible in ambulatory;

          -  Patient age > 18 years;

          -  Covered by health insurance

        Exclusion Criteria:

          -  Non-compliant patient

               -  Subject is pregnant, or lactating, or of childbearing potential and without
                  contraception;

               -  Active opportunistic infections (defining AIDS);

               -  Known hypersensibility to abacavir or lamivudine or dolutegravir;

               -  Patients harboring HLA B*5701;

               -  Major overweight (BMI ≥ 40);

               -  Weight <40 kg;

               -  Creatinine clearance < 50ml/min;

               -  Cirrhosis or severe liver failure (factor V < 50%);

               -  Life Prognosis threatened within 6 months;

               -  Circumstances that may impair judgment or understanding of the information given
                  to the patient;

               -  Co-medication with carbamazepin, oxcarbamazepin, fosphenytoïn, phenobarbital,
                  phenytoïn, primidon, St John's wort or dofetilid;

               -  Malabsorption syndromes;

               -  The following laboratory criteria:

                    -  Serum AST,ALT > 5 x upper limit of normal (ULN)

                    -  Thrombocytopenia with platelet count < 50.000/ml

                    -  Anemia with hemoglobin < 8g/dl

                    -  Polynuclear neutrophil count < 500/mm3
      